DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2068)

Acute Myeloid Leukemia | Landscape & Forecast | Disease Landscape & Forecast

Acute Myeloid Leukemia | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment has been dominated by chemotherapy followed by allo-SCT in eligible patients. However, following a flurry of drug approvals in 2017 and 2018, the AML treatment landscape is undergoing a transformation. The entry of novel agents into the treatment paradigm will enable the increasingly personalized treatment of patients, based on the characteristics of their disease and specific biomarkers. However, several areas of unmet need remain. Notably, patients unfit for intensive chemotherapy induction and relapsed/refractory AML patients offer significant commercial opportunity for innovative agents.

Label expansions and new drug approvals (e.g., FLT3 inhibitors, apoptosis-inducing agents) will fuel substantial growth of the AML therapy market over the 2017-2027 forecast period. This report provides insight on how treatment options for AML are likely to change over the 2017-2027 forecast period. It also analyzes the current and future earnings potential of AML therapies.

Questions answered:

  • What are the key drivers of growth over this period? What will be the major constraints on therapy sales? What are the drug development activities of note? What challenges and opportunities remain?
  • What is thought-leader opinion of emerging therapies and drug classes? For which patient populations will these agents be positioned? Will second-generation FLT3 inhibitors receive approval in the markets under study? How will use of these agents affect prescribing of other agents for AML?
  • How do key opinion leaders view the use of emerging therapies in the maintenance setting? Will maintenance therapy become a part of standard AML treatment in the future?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 17 country-specific interviews with thought leaders.

Epidemiology: Diagnosed incident cases of de novo AML and AML with MDS-related changes.

Population segments in market forecast: First-line AML, younger patients (aged < 60); first-line AML, older patients (aged ≥ 60); second-line AML, younger patients (aged < 60); second-line AML, older patients (aged ≥ 60); third-line AML.

Emerging therapies: Phase III: 11 drugs; Phase II: 27 drugs.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • June 2019
      • March 2019
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Acute Myeloid Leukemia?
        • What Factors Are Constraining the Market for Acute Myeloid Leukemia?
      • Segment-Specific Trends
        • First-Line AML, Younger Patients (Aged <60)
        • First-Line AML, Older Patients (Aged ≥60)
        • Second-Line AML, Younger Patients (Aged <60)
        • Second-Line AML, Older Patients (Aged ≥60)
        • Third-Line AML
    • Forecast
      • Market Forecast Downloads
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Disease Pathophysiology
      • Staging Systems in AML
      • Risk Stratification in AML
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • AML Transformation from Prior MDS
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Hypomethylating Agents
        • Antibody Drug Conjugates
        • FLT3 Inhibitors
        • Topoisomerase II Inhibitors
        • IDH Inhibitors
        • Apoptosis-Inducing Agents
        • Sonic Hedgehog Pathway Inhibitors
      • Medical Practice
        • First-Line AML, Older Patients (Aged ≥60)
        • First-Line AML, Younger Patients (Aged <60 Years)
        • Relapsed/Refractory AML
        • First-Line APL
        • Relapsed/Refractory APL
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in AML
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • FLT3 Inhibitors
        • Hypomethylating Agents
        • E-Selectin Inhibitors
        • HDAC Inhibitors
        • Apoptosis-Inducing Agents
        • NEDD8-Activating Enzyme Inhibitors
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Acute Myeloid Leukemia Bibliography

Already a Client? Log in to access this report.

  • Pub Date: June 2019
  • Author(s): Jorrit Schafer, M.Sc.,Ph.D; Atul Sharma, MPH
  • Jorrit Schäfer, , is a business insights analyst at Decision Resources Group. Prior to joining DRG, Dr. Schäfer worked as a postdoctoral research associate at Imperial College London, where he studied the impact of antibiotic stress on RNA repair in bacteria. Dr. Schäfer holds a in molecular medicine and a in molecular cell biology from Imperial College London.

  • Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.

Purchase Report

Recent reports:
You may also be interested in: